Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA – Get Rating) traded up 7.6% during trading on Monday . The company traded as high as $7.09 and last traded at $7.09. 8,338 shares changed hands during trading, a decline of 73% from the average session volume of 30,505 shares. The stock had previously closed at $6.59.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on the company. Brookline Capital Management restated a “buy” rating on shares of Hepion Pharmaceuticals in a research report on Tuesday, January 31st. Alliance Global Partners assumed coverage on Hepion Pharmaceuticals in a research report on Monday, January 23rd. They set a “buy” rating on the stock.
Hepion Pharmaceuticals Stock Performance
The firm has a market capitalization of $25.27 million, a P/E ratio of -0.56 and a beta of 1.63. The stock has a 50-day moving average of $13.83 and a 200 day moving average of $12.20.
Institutional Investors Weigh In On Hepion Pharmaceuticals
Hepion Pharmaceuticals Company Profile
Hepion Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease.
- Get a free copy of the StockNews.com research report on Hepion Pharmaceuticals (HEPA)
- How to Calculate Stock Growth
- 7 Best Retail Stocks to Invest in
- 3 Home Improvement Stocks to Renovate Your Portfolio
- Beam Global Shines Brightly in the EV Infrastructure Space
- Canoo Bottoms As Production Ramp Gets Closer
Receive News & Ratings for Hepion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hepion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.